Subramanian v. Lupin Inc.

Background

Veerappan Subramanian sued individually and as Seller Representative for VGS Pharma, LLC, Mendham Holdings, LLC, and Govindammal Subramanian and Anu Radha Subramanian, collectively called the Sellers. The claims arose from Lupin Inc.’s 2016 acquisition of two pharmaceutical companies under a Purchase and Sale Agreement. Subramanian asserted breach-of-contract and declaratory-judgment claims. Lupin asserted counterclaims against the Sellers for breach of contract, fraud, and a declaratory judgment.

The Sellers moved for partial summary judgment, which asks the court to resolve part of a case without a trial when the evidence shows there is no genuine dispute requiring a trial. Magistrate Judge Katharine Parker recommended granting the motion as to certain categories of damages and denying the rest. Specifically, the recommendation would grant the motion on Lupin’s breach-of-contract counterclaim to the extent Lupin sought lost profits and lost opportunity damages. It would also grant the motion on Lupin’s fraud claim to the extent Lupin sought consequential damages in the form of unrealized profits.

Review of the Report and Recommendation

The Sellers objected to the recommendation. They argued, among other things, that the agreement’s closing-adjustment process was a mandatory and exclusive remedy; that Lupin could not reasonably rely on the Sellers’ representations because of contractual disclaimers; that the report overlooked evidence and arguments; and that Lupin’s damages theories were impermissible.

The district court explained that specific objections to a magistrate judge’s report are reviewed independently, while portions without specific objections are reviewed for clear error. The court concluded that most of the Sellers’ objections repeated arguments already presented to Judge Parker and found no clear error in the recommendation.

The court agreed with the recommendation that the agreement did not make the closing-adjustment process the exclusive remedy for the alleged contract breaches. It also found no error in the conclusion that Lupin could pursue its fraud claim despite the Sellers’ reliance-disclaimer arguments. The court found that the record did not establish that Lupin lacked reasonable reliance and that the extent of Lupin’s investigation and access to information remained disputed or unclear.

The court further upheld the recommendation’s treatment of damages. It rejected the Sellers’ argument that Lupin’s theory based on the difference between the purchase price and the assets’ true value was unavailable, stating that such damages were permitted if proven. It also found no clear error in allowing Lupin’s theory concerning increased inventory costs related to Methergine, rather than treating that theory as barred lost-profit damages.

Ruling

Judge Ronnie Abrams adopted Judge Parker’s Report and Recommendation in its entirety. The Sellers’ motion for partial summary judgment was granted with respect to Lupin’s breach-of-contract counterclaim to the extent it sought lost profits and lost opportunity damages. The motion was also granted with respect to Lupin’s fraud claim to the extent it sought consequential damages in the form of unrealized profits. The motion was denied as to the remainder.

The court separately granted the parties’ requests to file Sellers’ memorandum of law and Lupin’s opposition brief in redacted form, finding the proposed redactions narrowly tailored to protect Lupin’s confidential information about a pharmaceutical product’s launch strategy. The court directed Sellers to file an unredacted version of their objections to the report on the public docket by October 19, 2020. The Clerk of Court was directed to terminate the motions at Dockets 285, 376, and 381.